SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours

About this trial

This study includes patients with primary non small cell lung cancer (NSCLC) and those with oligometastatic disease who have a single lung lesion. The oligo metastatic state refers to a stage of disease where the cancer has spread beyond the primary site of disease to another/a few other locations. Lung cancer is a common cancer worldwide. NSCLC makes up a large proportion of all lung cancers. The most common course of treatment for patients with small volume lung tumours is surgery. That said, approximately one quarter of patients are not suitable for surgery. These patients are treated with radiation therapy. Most commonly for patients with NSCLC this radiation therapy is delivered over 30-33 treatments. For oligometastatic disease there is currently no international agreement on the best course of treatment but recent evidence suggests treatments such as stereotactic ablative radiation therapy (SABR) may improve outcomes. This study looks at delivering the same overall dose of radiation but in 8 treatments rather than 30-33 using a method called image guided SABR. The study is aiming to determine the safety of delivering the radiation therapy in 8 treatments in terms of side effects experienced up to one year after treatment. All patients on this study will receive the same treatment. Patients will be monitored closely throughout their treatment and for another 5 years after the end of treatment. All patients will also be asked to fill in quality of life questionnaires at certain points during the study.

Patient Profile

Patients with inoperable (medically or by patient choice), early stage, high-risk centrally located lung cancer (primary lung cancer or oligometastatic cancer with one lung lesion).

Where’s this trial being run?

Beacon Hospital, St Luke’s Radiation Oncology Network @ St James’s Hospital, and St Luke’s Radiation Oncology Network @ St Luke’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours
Number: 18-33
Full Title:

Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours

Principal Investigator: Prof John Armstrong
Type: In-House

Cancer Trials Ireland

Recruitment Started: Global: 22-Dec-2020
Ireland: 22-Dec-2020
Global Recruitment Target: 68
Ireland Recruitment Target: 68